|
|
???tair.name??? >
???browser.page.title.author???
|
"feng y h"???jsp.browse.items-by-author.description???
Showing items 1-25 of 27 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-08-12T06:27:35Z |
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
|
Yeh D.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Wang H.-C.; Rau K.-M.; Feng Y.-H.; Chang Y.-C.; Lee K.-D.; Ou-Yang F.; Kuo W.-H.; KING-JEN CHANG; Lin Y.-C.; Tseng L.-M.; Hou M.-F. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 國立成功大學 |
2022 |
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
|
Chen, Chen C.-T.;Feng, Y.-H.;Yen, C.-J.;Chen, S.-C.;Lin, Y.-T.;Lu, Lu L.-C.;Hsu, C.-H.;Cheng, A.-L.;Shao, Y.-Y. |
| 國立成功大學 |
2022 |
An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline
|
Chang, W.-T.;Liu, C.-F.;Feng, Y.-H.;Liao, C.-T.;Wang, J.-J.;Chen, Z.-C.;Lee, H.-C.;Shih, J.-Y. |
| 國立成功大學 |
2022 |
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
|
Wu, N.-C.;Feng, Y.-H.;Kuo, Y.H.;Chen, W.-Y.;Wu, H.-C.;Huang, C.-T.;Wang, Wang W.-C.;Kang, N.-W.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立成功大學 |
2022 |
The impact of COVID-19 on cardio-oncology care in Taiwan
|
Kang, N.-W.;Feng, Y.-H.;Chen, Z.-C.;Chang, W.-T. |
| 臺大學術典藏 |
2021-12-01T06:03:00Z |
Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan
|
Chen C.-Y.; Kumar R.N.; Feng Y.-H.; Ho C.-H.; You J.-Y.; Liao C.-C.; Tseng C.-H.; Mavros P.; Gerth W.C.; YEE-CHUN CHEN |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-05-06T01:52:45Z |
Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan
|
Chen C.-Y.; Kumar R.N.; Feng Y.-H.; Ho C.-H.; You J.-Y.; Liao C.-C.; Tseng C.-H.; Mavros P.; Gerth W.C.; YEE-CHUN CHEN |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 國立成功大學 |
2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
|
Harding, J.J.;Yang, T.-S.;Chen, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Ho, C.-L.;Huang, W.-T.;El, Dika I.;Akce, M.;Tan, B.;Cohen, S.A.;Meyer, T.;Sarker, D.;Lee, D.-W.;Ryoo, B.-Y.;Lim, H.Y.;Johnston, A.;Bomalaski, J.S.;O’Reilly, E.M.;Qin, S.;Abou-Alfa, G.K. |
| 國立成功大學 |
2021 |
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
|
Hsu, J.C.;Nguyen, P.-A.;Chen, Y.-T.;Yang, S.-C.;Lin, C.-C.;Yang, Yang Y.-H.;Lin, Y.-C.;Hsia, T.-C.;Hsieh, Hsieh H.-C.;Wu, J.-S.;Chang, Chang C.-P.;Feng, Y.-H.;Lin, P.-C.;Hsu, P.-C.;Tzeng, H.-E.;Chien, S.-C.;Chang, W.-C.;Chang, Chang C.-C.;Yang, H.-C.;Lee, C.M.;Lu, C.Y. |
| 國立成功大學 |
2021 |
Narrative review-cardiovascular evaluation before radiotherapy for patients with breast cancer and other malignancies
|
Chang, W.-T.;Feng, Y.-H.;Chen, Z.-C.;Wu, Y.-W. |
| 臺大學術典藏 |
2020-09-29T01:48:07Z |
Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan
|
Gerth W.C.; YEE-CHUN CHEN; Mavros P.; Tseng C.-H.; Liao C.-C.; You J.-Y.; Ho C.-H.; Feng Y.-H.; Chen C.-Y.; Kumar R.N. |
| 國立成功大學 |
2020 |
Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer—From bedside to bench
|
Chang, W.-T.;Feng, Y.-H.;Kuo, Y.H.;Chen, W.-Y.;Wu, H.-C.;Huang, C.-T.;Huang, T.-L.;Chen, Z.-C. |
| 國立成功大學 |
2020 |
The Expression of MicroRNA-21 in Bone Marrow Fluid is an Indicator of Hematological Disorders and Mortality
|
Chang, W.-T.;Huang, T.-L.;Chen, Z.-C.;Feng, Y.-H. |
| 國立成功大學 |
2020 |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial
|
Saura, C.;Oliveira, M.;Feng, Y.-H.;Dai, M.-S.;Chen, S.-W.;Hurvitz, S.A.;Kim, S.-B.;Moy, B.;Delaloge, S.;Gradishar, W.;Masuda, N.;Palacova, M.;Trudeau, M.E.;Mattson, J.;Yap, Yap Y.S.;Hou, M.-F.;De, Laurentiis M.;Yeh, Yeh Y.-M.;Chang, H.-T.;Yau, T.;Wildiers, H.;Haley, B.;Fagnani, D.;Lu, Y.-S.;Crown, J.;Lin, J.;Takahashi, M.;Takano, Takano T.;Yamaguchi, M.;Fujii, T.;Yao, B.;Bebchuk, J.;Keyvanjah, Keyvanjah K.;Bryce, R.;Brufsky, A.;Investigators, NALA |
| 國立成功大學 |
2019 |
Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking
|
Kuo, Y.-.H.;Shiau, A.-L.;Tung, C.-L.;Su, Y.-C.;Li, C.-F.;Su, B.-H.;Tsao, C.-J.;Wu, C.-L.;Feng, Y.-H.;Wu, P. |
| 國立成功大學 |
2019 |
Proteomic profile of sorafenib resistance in hepatocellular carcinoma; GRP78 expression is associated with inferior response to sorafenib
|
Feng, Y.-H.;Tung, C.-L.;Su, Y.-C.;Tsao, C.-J.;Wu, T.-F. |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國立成功大學 |
2018 |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen, C.-J.;Kim, T.-Y.;Feng, Y.-H.;Chao, Y.;Lin, D.-Y.;Ryoo, B.-Y.;Huang, D.C.-L.;Schnell, D.;Hocke, J.;Loemb�, A.-B.;Cheng, A.-L. |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
| 國立成功大學 |
2014-07 |
Elovl6 overexpression promotes liver carcinogenesis
|
Shiau, A. L.; Su, Y. C.; Feng, Y. H.; Wu, H. T.; Huang, Y. S.; Wu, P.; Chang, C. J.; Wu, C. L. |
Showing items 1-25 of 27 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
